Measuring the pharmacodynamic effects of a novel Hsp90 inhibitor on HER2/ neu expression in mice using 89Zr-DFO-trastuzumab Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Benzodioxoles
  • Deferoxamine
  • Genes, erbB-2
  • HSP90 Heat-Shock Proteins
  • Purines
  • Zirconium

abstract

  • The results indicate that (89)Zr-DFO-trastuzumab provides quantitative and highly-specific delineation of HER2/neu positive tumors, and has potential to be used to measure the efficacy of long-term treatment with Hsp90 inhibitors, like PU-H71, which display extended pharmacodynamic profiles.

publication date

  • January 25, 2010

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC2810330

Digital Object Identifier (DOI)

  • 10.1371/journal.pone.0008859

PubMed ID

  • 20111600

Additional Document Info

start page

  • e8859

volume

  • 5

number

  • 1